Skip to main content

Table 3 Potential risk factors for the first major infection in 103 patients with SLE

From: Deficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosus

  = 1 major infection (n = 23) No major infection (n = 80) p value
Laboratory variables    
Functional MBL serum level, μg/mla 1.60 (0.04–7.00) 1.40 (0.04–7.60) 0.316
Functional MBL serum level <0.05 μg/ml 2/23 (9%) 11/80 (14%) 0.522
MBL-induced C4 deposition on mannan, percentagea 64.8 (3.4–400) 71.1 (1.1–400) 0.550
MBL-induced C4 deposition on mannan <10% 5/23 (22%) 16/80 (20%) 0.856
MBL pathway activity, percentagea 14.1 (0.1–111) 17.3 (0.1–119) 0.806
MBL pathway activity <10% 10/23 (44%) 34/80 (43%) 0.934
Clinical variables    
Disease duration at follow-up, years 12.5 ± 7.4 5.1 ± 5.7 0.0001
Previous SLE glomerulonephritis 10/23 (44%) 10/80 (10%) 0.001
Treatment variables Use <3 months before the first major infection Previous use ever since lupus diagnosis  
Oral corticosteroids 17/23 (74%) 41/80 (51%) 0.916
Intravenous methylprednisolone 5/23 (22%) 9/80 (11%) 0.204
Hydroxychloroquine 6/23 (26%) 70/80 (88%) 0.0001
Methotrexate 0/23 (0%) 9/80 (11%) 0.094
Azathioprine 8/23 (35%) 21/80 (26%) 0.424
Oral cyclophosphamide 1/23 (4%) 1/80 (1%) 0.373
Intravenous cyclophosphamide 4/23 (17%) 4/80 (5%) 0.065
  1. Except where indicated otherwise, values are presented as the mean ± standard deviation. aValues are presented as the median (range). MBL, mannose-binding lectin; SLE, systemic lupus erythematosus.